Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety and Ocular Hypotensive Efficacy and Optimum Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension in the United States

NCT03310580 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.

NCT NCT03310580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03310580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety and Ocular Hypotensive Efficacy and Optimum Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension in the United States
Lead sponsor
Aerie Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2017
Completion date
October 25, 2018
Enrollment
42 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

primary open angle glaucoma or ocular hypertension